Collateral damage during antibiotic treatment of *C. difficile* infection in the aged host: Insights into why recurrent disease happens

Jae Hyun Shin and Cirle A. Warren

University of Virginia School of Medicine, Department of Medicine, Division of Infectious Diseases and International Health

**Abstract**

*Clostridium difficile* infection (CDI) is one of the most common causes of healthcare-associated infections but an even bigger problem for the aging population. Advanced age leads to higher incidence, higher mortality, and higher recurrences. In our study, recently published in the Journal of Infectious Diseases, we investigated the effect of aging on CDI using a mouse model. We were able to demonstrate that aging leads to worse clinical outcomes, as well as lead to changes in microbiota composition and lower antibody production against *C. difficile* toxin A, but not toxin B. An association between advanced age and lower antibody production against *C. difficile* is a new finding which would explain the effect of aging on CDI outcome. Vancomycin, an anti-*C. difficile* antibiotic, led to similar changes in antibody response, suggesting a connection between microbiome and antibody response in the context of aging, which would require a much more nuanced look at the treatment of CDI.

**Keywords**

aging; *Clostridium difficile* infection; host response; humoral response; microbiome

---

*Clostridium difficile* Infection (CDI) is the most common pathogen to cause healthcare-associated infections in the United States and is responsible for an excess cost to the healthcare system of at least 1 billion dollars annually. It is an even bigger problem for the aging population. Review of nationwide databases in the US in 2009 shows that the incidence of CDI in people older than 65 is about 10 times higher than in people younger than 65 across various databases. The severity of disease is also higher in the older population, with CDI-related deaths being the 18th most common cause of death in people 65 or older, and 92% of all deaths from CDI occurring in people 65 and older. Not only is aging a risk factor for developing CDI and for severe outcome, but also for recurrent CDI, with odds ratio for recurrence ranging between 1.75 to 6.0 in population older than 65 depending on various studies. These statistics suggest that an in-depth investigation into the relationship of advanced age to CDI is of increasing importance.

A unique problem with CDI is the high rate of recurrence. The recurrence rate after an initial episode of CDI is quite high for all patients, ranging from 13.5% to 28.8%. In addition to age older than age 65, other risk factors for recurrent disease include severe or fulminant underlying illness, additional antibiotic use after discontinuation of metronidazole or vancomycin, and low serum anti-toxin A IgG concentration. These risk factors suggest 2 main mechanisms which may influence CDI recurrence: intestinal microbiota and antibody response. The intestinal microbiota, the population of bacteria which reside in healthy human intestines, provide resistance to *C. difficile* colonization and therefore pathogenesis of CDI usually involves disruption of this normal microbiota. The diversity of the intestinal microbiota is lower in patients with CDI compared with healthy patients, and is decreased further in recurrent episodes. Antibiotic treatment changes the composition of the microbiota from that of a healthy host and decreases the bacterial diversity. Since treatment of CDI is with antibiotics directed against *C. difficile* bacteria such as metronidazole or vancomycin, these antibiotics themselves can cause more microbiota...
changes which may make the host prone to recurrence. Thus, treatment of CDI presents a paradoxical situation where treatment is necessary but the treatment is likely to increase the chance for recurrence. Antibody response, the second potential mechanism for predicting CDI recurrence, has been shown to be an important factor as well, specifically antibody response against C. difficile toxins. Although different antibodies were shown to be important in different studies – IgM anti-toxin A, IgG anti-toxin A, IgA anti-toxin A, IgA anti-toxin B – they all show association between stronger antibody response and lower likelihood of recurrence. Recent studies on piglet model of CDI and in humans showed that monoclonal antibodies directed against toxin B but not toxin A were effective in preventing recurrence of CDI. These studies confirm the important role anti-toxin B antibody plays in host defense against C. difficile and its importance in therapeutics. However, the described previously human studies did show an association of clinical outcome with anti-toxin A antibodies as well. These findings suggest that anti-toxin A antibody along with anti-toxin B antibody levels may be a measure of the robustness of the humoral immune response and still correlates with clinical outcome from CDI. In our model, anti-toxin A antibodies showed the most consistent and reproducible results. IgG anti-toxin B antibodies were measured, but did not show significant difference between young and aged mice or before or after treatment. These inconsistent findings may be secondary to technical challenges encountered with the anti-toxin B assay, including limited amounts of mouse sera for repeat assays at adjusted toxin B and antibody loads and incubation times. However, we found that the anti-toxin A responses we have observed provide insights into what may be occurring in the aged infected host. So far there are no studies looking into factors that affect antibody response to C. difficile. Aging has been associated with decreased ability to produce high affinity immunoglobulins and lower antibody response to vaccines but has not been shown to have association with antibody response to C. difficile specifically.

In our study, we used a mouse model of CDI to study the effect of aging on CDI, specifically focusing on severity and relapse, and measuring antibody response and intestinal microbiota to explore possible mechanisms of higher recurrence. Aged mice (8 weeks old) during infection with C. difficile. For the study of CDI pathogenesis, Syrian hamsters were first used as an animal model and used to demonstrate the role of toxins in pathogenesis. Key issues with this model was that the disease was uniformly fatal while diarrhea was not always present, which does not closely replicate the clinical manifestations of human CDI, which is not uniformly fatal, and can often be a mild-to-moderate diarrhea. An additional limitation of the model is that there are relatively few commercially available reagents and assays to study various aspects of immune response to infection and pathogenesis. Genetic techniques to facilitate mechanistic studies are, likewise, limited in the hamster model. The mouse model of CDI using broad spectrum antibiotic exposure was described by Chen et al. which leads to varying severity of disease in accordance with the challenge dose, with diarrhea, more closely mimicking human CDI and could reflect the range of clinical manifestations seen in human CDI. Use of a mouse model offers more tools in the way of readily available mouse specific reagents and genetically modified animals as well. Mouse model also has limitations, one of the limitation being that the susceptibility of the mice to infection varies with microbiota, which is affected by the environment and diet. This may actually more closely reflect human disease than other models, but makes controlling for all the variables difficult. Another limitation is that the immune system of mice is not exactly analogous to humans, which is the limitation for other animal models as well. Furthermore, outcome of infection may vary between mouse strains and C. difficile strains. The piglet model has recently come into the spotlight specifically because of overlap in strains infecting humans. CDI infection causes enteritis during the first week of life, and is now the most commonly diagnosed cause of enteritis in neonatal pigs. This is interesting because C. difficile in humans had first been isolated in the gut of neonates, but they rarely cause disease. Despite this obvious difference in pathogenesis, a study using gnotobiotic piglet model has shown clinical outcome and histopathologic changes similar to human disease. The piglet model has also recently been used to test the utility of anti-toxin antibody therapy in CDI. This new model presents another good methodology to study effects of therapeutic agents, as it closely resembles human disease in the effect of anti-toxin antibody therapy. As noted prior...
however, CDI, although reported in pediatric patients, is more often a disease affecting adults and especially the elderly population, which was the purpose of our study. Therefore in studies looking at the effect of aging or where the age of the host is a factor, another animal model may be more appropriate. For our study, with aging at the end of life, correlating with advanced age such as 65 y or older in humans, being an important factor instead of prematurity in the first year of life as would be applicable in piglet models, along with the need to measure the microbiota effect, the mouse model is optimal. It should be noted that there is no single animal model that is best reflective of human disease in CDI at present, and while the mouse model is one of the most widely used due to various factors outlined above, it is still an imperfect model, and is a limitation of this study. Aging in the mouse model was associated with higher mortality and prolonged weight loss after CDI, which mirrors the effect of aging observed in the human host.\textsuperscript{7,27,28,29} However, the differences were even more striking in the relapse experiment. In this experiment, starting 24 hours after infection, mice were treated with vancomycin which is the treatment of choice for severe CDI.\textsuperscript{14,30-32} Treatment with vancomycin prevented the development of symptomatic disease while on treatment but resulted in a relapse of symptomatic disease after stopping vancomycin. During this relapsed disease the difference in clinical outcome was even more dramatic, with 75% mortality in aged mice compared with 0% in young mice (Fig. 1). During relapse, aged mice also experienced more weight loss and higher disease scores.

The striking difference in mortality seen in relapsed disease between aged and young mice raises the question of what is different with initial infection and relapsed disease that makes aged mice so much more susceptible. Changes in the microbiome, with cumulative changes expected from repeated use of antibiotics, would be an obvious explanation.\textsuperscript{12} However, conventional wisdom so far would suggest that microbiome mainly affects the susceptibility of the host to becoming colonized with \textit{C. difficile} bacteria\textsuperscript{10} rather than the

![Figure 1](image)

**Figure 1.** Effect of treatment with vancomycin (50 mg/kg/day) for 5 d (days 1–5 after infection) in Clostridium difficile--infected young mice (aged 2 months) and aged mice (aged 18 months). A. Weight change from baseline, before infection, up to the day of death. *P < .05 by 2-way analysis of variance (ANOVA) with the Bonferroni correction. B. Disease severity scores of surviving mice. *P < .001 by 2-way ANOVA with the Bonferroni correction. C. Survival curve. P < .0001 by the log-rank (Mantel–Cox) test. Figure taken from van Opstal et al., Vancomycin treatment alters humoral immunity and intestinal microbiota in an aged mouse model of Clostridium difficile infection. J Infect Dis 2016. © Edward van Opstal, Glynis L. Kolling, John H. Moorell, Christine M. Coquery, Nekethia S. Wade, William M. Loo, David T. Bolick, Jae Hyun Shin, Loren D. Erickson, and Cirile A. Warren. Reproduced by permission of the authors. Permission to reuse must be obtained from the rightsholder.
clinical outcome once infection occurs. The finding from this study highlights the critical influence of the microbiota on the outcome of CDI, even after overt disease is established.

Our findings suggest that the 2 important mechanisms that affect rate of recurrence, intestinal microbiota and humoral response, may be linked and explain the difference in outcome between initial versus relapsed disease (Fig. 2). We discovered that vancomycin-treated mice, compared with mice who did not receive any treatment after infection, produced significantly lower levels of IgG and IgA antibodies against *C. difficile* toxin A (TcdA). Treatment with vancomycin, the treatment of choice against CDI, led to temporary relief from symptoms, but eventually led to even higher mortality in aged mice. Vancomycin also led to lower IgG and IgA response to TcdA. These finding suggest an association with microbiota and antibody response. Modified from figure in Shin et al. Older Is Not Wiser, Immunologically Speaking: Effect of Aging on Host Response to *Clostridium difficile* Infections. J. Gerontol. A. Biol. Sci. Med. Sci. 2016.

**Figure 2.** Effect of aging and antibiotic use on *C. difficile* infection outcome. *C. difficile* infection (CDI) experiments using an aged mouse model show significantly worse clinical outcome, including higher mortality. Aged mice also had an alteration in the intestinal microbiota compared with young mice and lower levels of IgG and IgA antibodies against *C. difficile* toxin A (TcdA). Treatment with vancomycin, the treatment of choice against CDI, led to temporary relief from symptoms, but eventually led to even higher mortality in aged mice. Vancomycin also led to lower IgG and IgA response to TcdA. These finding suggest an association with microbiota and antibody response. Modified from figure in Shin et al. Older Is Not Wiser, Immunologically Speaking: Effect of Aging on Host Response to *Clostridium difficile* Infections. J. Gerontol. A. Biol. Sci. Med. Sci. 2016.

antibody response to *C. difficile* has been shown to be the difference between symptomatic infection and asymptomatic colonization as well as between recurrence and resolution of CDI. These findings suggest an important role for antibody response in CDI pathogenesis.

Regarding the link between microbiota and antibody response, there is a paucity of data in the literature so far. Among the different immunoglobulin classes, IgA is secreted across the intestinal epithelium into the intestinal lumen, where it binds to microbes and other antigens, and can coat and agglutinate its targets to prevent direct interaction with the host, averting a potentially harmful stimulation of the immune system. Consistent with this hypothesis, people deficient in IgA have more bacteria from taxa with potentially inflammatory properties. IgA is generated by gut plasma cells with cooperation of epithelial cells, dendritic cells, and innate lymphoid cells. Therefore, number of IgA-expressing cells in lymphoid tissue are greatly reduced in germ free animals. The effect of microbiota on IgA secretion was demonstrated in a human study, where the number of *Bifidobacterium* and *Lactobacillus* species in the early intestinal microbiota in infants was associated with total levels of secretory IgA measured in the saliva at 6 months. These known findings suggest an interesting possibility that differential IgA binding in different
hosts may lead to a different effective bacterial load or toxin load in CDI leading to differences in outcome despite similar total bacterial or toxin load in the intestine. However, this does not explain the effect of microbiota in the adult host or interaction between the microbiota and other immunoglobulins such as IgG and IgM and its effect on CDI. There are studies demonstrating that probiotic treatment leads to an improvement in IgG and IgA antibody production with influenza vaccines, suggesting that microbiota-humoral immunity interaction in adult host after the initial development of immune system is possible.37,38

It is likely that there is an effect of aging on antibody response which is not related to the microbiota. In our study, even without antibiotics, aged mice had lower levels of serum IgG and IgA against toxin A at day 14; which has not been demonstrated previously. In human studies where they were both measured, association between age and antibody production was not observed, although both advanced age and antibody levels were highly correlated with recurrence rates.5,39 This study is the first to demonstrate an association with advanced age and lower antibody response to CDI. The finding has significant implications on the role of advanced age on CDI. The published findings in the literature suggest a strong relationship between antibody production and development of CDI,33,40 and recurrence.5,39 If the statement “aging leads to lower antibody response to C. difficile toxins” can be confirmed in subsequent studies, this would explain the reason for why the elderly are more susceptible to CDI and recurrence.

Investigation of aging as a factor in CDI presents a challenging problem. Aging is associated with numerous factors that influences CDI outcome such as antibiotic exposure, healthcare contact, and medical comorbidities, which needs to be controlled when studying the effect of aging.41 Another challenge is that the changes are detected in various systems simultaneously including humoral immunity and intestinal microbiota as we have seen, along with other factors such as innate immunity and gastrointestinal motility.41 These factors make study of the effect of aging on CDI crucial, however. The complex interplay of the host factors as detected by differences in aging will shed more light on the pathogenesis of CDI. It may also very well be applied to the investigation of aging as a factor in other infections.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**References**

[1] Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. N Engl J Med 2014; 370(13):1198-208; PMID:24670166; https://doi.org/10.1056/NEJMoa1306801

[2] Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55(suppl 2):S88-92; PMID:22752870; https://doi.org/10.1093/cid/cis335
[3] Olsen MA, Young-Xu Y, Stwalley D, Kelly CP, Gerding DN, Saeed MJ, Mahé C, Dubberke ER. The burden of Clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases. BMC Infect Dis 2016; 16(1):177; PMID:27102582; https://doi.org/10.1186/s12879-016-1501-7

[4] Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst 2011; 59(10):1-126.

[5] Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 2001; 357(9251):189-93; PMID:11213096; https://doi.org/10.1016/S0140-6736(00)35923-3

[6] Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis Off Publ Infect Dis Soc Am 2006; 42(6):758-64; https://doi.org/10.1086/501126

[7] Pépin J, Alary M-E, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis Off Publ Infect Dis Soc Am 2005; 40(11):1591-7; https://doi.org/10.1086/430315

[8] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372(9):825-34; PMID:25714160; https://doi.org/10.1056/NEJMoai408913

[9] Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, Xu H, Leffler DA, Kelly CP. Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection. Gastroenterology 2009; 136(4):1206-14; PMID:19162027; https://doi.org/10.1053/j.gastro.2008.12.038

[10] Borriello SP, Barclay FE. An in-vitro model of colonisation resistance to Clostridium difficile infection. J Med Microbiol 1986; 21(4):299-309; PMID:3723582; https://doi.org/10.1099/00222615-21-4-299

[11] Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372(16):1539-48; PMID:25875259; https://doi.org/10.1056/NEJMra1403772

[12] Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile –Associated Diarrhea. J Infect Dis 2008; 197(3):435-8; PMID:18199029; https://doi.org/10.1086/525047

[13] O’Sullivan O, Coakley M, Lakshminarayanan B, Conde S, Claesson MJ, Cusack S, Fitzgerald AP, O’Toole PW, Stanton C, Ross RP, et al. Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy. J Antimicrob Chemother 2013; 68(1):214-21; PMID:22949626; https://doi.org/10.1093/jac/dks348

[14] Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 2010; 31(5):431-55; https://doi.org/10.1086/651706

[15] Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 2004; 22(7):848-56; PMID:15040937; https://doi.org/10.1016/j.vaccine.2003.11.030

[16] Bauer MP, Nibbering PH, Poxtor IR, Kuijper EJ, van Dissel JT. Humoral immune response as predictor of recurrence in Clostridium difficile infection. Clin Microbiol Infect 2014; 20(12):1323-8.

[17] Steele J, Mukherjee J, Parry N, Tzipori S. Antibody Against TcdB, but Not TcdA, Prevents Development of Gastrointestinal and Systemic Clostridium difficile Disease. J Infect Dis 2013; 207(2):323-30; PMID:23125448; https://doi.org/10.1093/infdis/jitsb69

[18] Wilcox MH, Gerding DN, Poxtor IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med 2017; 376(4):305-17; PMID:28121498; https://doi.org/10.1056/NEJMoai1602615

[19] Frasca D, Landin AM, Lechner SC, Ryan JG, Schwartz R, Riley RL, Blomberg BB. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J Immunol Baltim Md 1950 2008; 180(8):5283-90.

[20] Goronzky JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 2013; 14(5):428-36; PMID:23598398; https://doi.org/10.1038/ni.2588

[21] van Opstal E, Kolling GL, Moore JH, Coquery CM, Wade NS, Loo WM, Bolick DT, Shin JH, Erickson LD, Warren CA. Vancomycin treatment alters humoral immunity and intestinal microbiota in an aged mouse model of Clostridium difficile infection. J Infect Dis 2016; 214(1):130-9. jiw071; PMID:26917573; https://doi.org/10.1093/infdis/jiw071

[22] Chang TW, Bartlett JG, Gerding DN, Johnson S, Kelly CP. Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection. Gastroenterol Engl J Med 2015; 372(9):825-34; PMID:25714160; https://doi.org/10.1056/NEJMoai408913
[25] Songer JG, Anderson MA. Clostridium difficile: an important pathogen of food animals. Anaerobe 2006; 12 (1):1-4; PMID:16701605; https://doi.org/10.1016/j.anaerobe.2005.09.001

[26] Steele J, Feng H, Parry N, Tzipori S. Piglet Models of Acute or Chronic Clostridium difficile Illness. J Infect Dis 2010; 201(3):428-34; PMID:20039803; https://doi.org/10.1086/649799

[27] Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173(9):1037-42; https://doi.org/10.1503/cmaj.050978

[28] Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical Risk Factors for Severe Clostridium difficile–associated Disease. Emerg Infect Dis 2009; 15(3):415-22; PMID:19239754; https://doi.org/10.3201/eid1503.080312

[29] Louie TJ, Miller MA, Crook DW, Lentnek A, Bernard L, Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical Risk Factors for Severe Clostridium difficile Infection Outcomes. Clin Infect Dis 2016; 63(6):730-4; PMID:27365387; https://doi.org/10.1093/cid/ciw364

[30] Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45 (3):302-7; https://doi.org/10.1086/519265

[31] Johnson S, Louie TJ, Gerding DN, Corney OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM. Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis Off Publ Infect Dis Soc Am 2014; 59(3):345-54; https://doi.org/10.1093/cid/ciu313

[32] Stevens VW, Nelson RE, Schwab-Daugherty EM, Khader K, Jones MM, Brown KA, Greene T, Croft LD, Neuhauser M, Glassman P, et al. Comparative effectiveness of Vancomycin and Metronidazole for the prevention of recurrence and death in patients with Clostridium difficile Infection. JAMA Intern Med 2017; 177(4):546-53; PMID:28166328; https://doi.org/10.1001/jamainternmed.2016.9045

[33] Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342 (6):390-7; PMID:10666429; https://doi.org/10.1056/NEJM200002103420604

[34] Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016; 535 (7610):75-84; PMID:27383982; https://doi.org/10.1038/nature18848

[35] Friman V, Nowrouzian F, Adlerberth I, Wold AE. Increased frequency of intestinal Escherichia coli carrying genes for S fimbriae and haemolysin in IgA-deficient individuals. Microb Pathog 2002; 32(1):35-42; PMID:11782119; https://doi.org/10.1006/mpat.2001.0477

[36] Sjögren YM, Tomicic S, Lundberg A, Böttcher MF, Björksten B, Sverremark-Ekström E, Jenmalm MC. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses: Gut microbiota and immune responses. Clin Exp Allergy 2009; 39(12):1842-51; PMID:19735274; https://doi.org/10.1111/j.1365-2222.2009.03326.x

[37] Bosch M. Lactobacillus Plantarum Cect315 Y Cect7316 Estimula La Producción De Inmunoglobulinas Antivirales. Nutr Hosp 2012; 27(2):504-9; PMID:22732975

[38] Gupta SB, Mehta V, Dubberke ER, Zhao X, Dorr MB, Guris D, Molrine D, Leney M, Miller M, Dupin M, et al. Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence. Clin Infect Dis 2016; 63(6):730-4; PMID:27365387; https://doi.org/10.1093/cid/ciw364

[39] Gupta SB, Mehta V, Dubberke ER, Zhao X, Dorr MB, Guris D, Molrine D, Leney M, Miller M, Dupin M, et al. Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence. Clin Infect Dis 2016; 63(6):730-4; PMID:27365387; https://doi.org/10.1093/cid/ciw364

[40] Wullt M, Noren T, Ljungh A, Akerlund T. IgG Antibody Response to Toxins A and B in Patients with Clostridium difficile Infection. Clin Vaccine Immunol 2012; 19(9):1552-4; PMID:22787196; https://doi.org/10.1128/CVI.0210-12

[41] Shin JH, High KP, Warren CA. Older is not wiser, immunologically speaking: Effect of aging on host response to Clostridium difficile infections. J Gerontol A Biol Sci Med Sci 2016; 71(7):916-22; PMID:26809495; https://doi.org/10.1093/gerona/glv229